Two-Component Regulatory Systems in Urinary Tract Infections: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Giuseppe Valerio De Gaetano
,
Germana Lentini
,
Agata Famà
,
Francesco Coppolino
,
Concetta Beninati

Two-component signaling systems (TCSs) are finely regulated mechanisms by which bacteria adapt to environmental conditions by modifying the expression of target genes. In bacterial pathogenesis, TCSs play important roles in modulating adhesion to mucosal surfaces, resistance to antibiotics, and metabolic adaptation. In the context of urinary tract infections (UTI), one of the most common types infections causing significant health problems worldwide, uropathogens use TCSs for adaptation, survival, and establishment of pathogenicity. 

  • UTI
  • TCSs
  • mutants
  • virulence genes

1. Uropathogenic Escherichia coli

Uropathogenic Escherichia coli (UPEC) is the major cause of UTI in humans with millions of hospitalizations and emergency visits each year [1][2]. UPEC uses several virulence factors to survive in the urinary tract such as pili, hemolysins, and flagella [3][4][5]. The best characterized E. coli virulence factors involved in UTI pathogenesis are surface-exposed or secreted [6] and are schematically listed in Table 1.
Table 1. Virulence factors of Uropathogenic E. coli (UPEC) in UTI.
Surface Virulence Factors Main Pathogenic Functions
Type 1 fimbriae Enhanced bacterial survival; Stimulation of inflammation;
Promotion of invasion; Biofilm growth; Binding to uroplakin
P fimbriae Binding to kidney glycosphingolipids;
Bacterial colonization of tubular epithelium
S fimbriae Binding to the lower human urinary tract and kidney;
Bacterial dissemination
Fimbrial Dr Binding to type IV collagen and to decay-accelerating factor (DAF)
Adhesin Afa Establishment of chronic and/or recurrent infection
Flagella Bacterial motility; Bacterial ascension from the bladder to kidneys
Secreted virulence factors Main pathogenic functions
α-haemolysin (HlyA) Lysis of erythrocytes and nucleated cells; Induction of apoptosis of host cells; Exfoliation of bladder epithelial cells
Cytotoxic necrotizing factor 1 (CNF1) Kidney invasion; Interference with phagocytosis;
Exfoliation of bladder cells
Secreted autotransporter toxin (SAT) Damage of bladder or kidney cells
UPEC belong to the extra-intestinal pathogenic strains (ExPEC) group, which is characterized by a high degree of genetic heterogeneity with an extensive range of different virulence factors. Almost all UPEC strains express type 1 pilus-associated protein FimH that binds to a variety of extracellular matrix components as well as mannose-containing host glycoproteins on umbrella cells [1][7][8]. Moreover, several adhesins, such as F1C pili, S pili, and the autotransporter proteins Upa, mediate the development of biofilms [9][10][11][12]. Biofilm assembly on urinary catheters renders UPEC extremely resistant to antibiotics and host immune responses [12]. Among host receptors implicated in mediating invasion of host cells, integrins [13], the complement regulatory protein CD46 [14], the complement decay-accelerating factor CD55 [15], and the flagellin sensor Toll-like receptor 5 (TLR-5) play major roles [16].
Furthermore, UPEC enter into bladder cells by dysregulating the actin cytoskeleton and promoting a zipper-dependent endocytosis pathway [17]. Once inside bladder cells, UPEC can meet alternative fates, including going back into the extracellular environment [18], replicate intracellularly to create IBCs [19][20] or persist intracellularly without multiplying [21][22]. Intracellular persistence is an effective strategy to avoid the action of antibiotics because of the intrinsic impermeability of the urothelial barrier and the inability of most drugs to cross cell membranes [23]. It is interesting to note that, in order to adapt to host microenvironments, InPEC express virulence factors similar to those expressed by UPEC, including fimbrial adhesins [24][25]. Several of these adhesins are also expressed by other uropathogens, such P. mirabilis and K. pneumoniae, and are considered as suitable targets for anti-adhesive therapeutics [26][27].
Since osmolarity can vary considerably in the urinary tract, UPEC has developed strategies to sense external osmolar fluctuations and adapt to these changes [28][29]. One way to accomplish this is the EnvZ-OmpR TCS, which senses osmotic changes, upregulates the expression of the outer membrane porin proteins OmpF or OmpC, and modulates the expression of type 1 pili via activation of the transcriptional regulator OmpR [30][31][32]. The clinical isolate NU149, deleted of the ompR gene (ΔompR), drastically reduced its rate of growth, compared to the WT parental strain, in the presence of increasing NaCl concentrations, whereas complementation with a functional ompR gene restored bacterial growth at WT levels [33]. Furthermore, growth of ΔompR bacteria was further impaired when exposed to high NaCl concentrations in the presence of an acidic pH, thus mimicking the environmental conditions found in human urine. High concentrations of urea and sucrose in the growth medium also led to reduced growth of the ΔompR strain. The phenotype of ΔompR E. coli, was mimicked by strains carrying a single point mutation at position 55, the site of EnvZ-mediated phosphorylation [33].
The mouse urine has a pH ranging from pH 5.5 to 7.0 and osmolarities ranging from 350 to 600 mM [33]. In in vivo studies performed after inoculation of mice with ompR mutants, viable ΔompR bacteria recovered from the bladder were markedly reduced at one-day post-challenge compared with WT bacteria, while there was only a tendency towards lower ΔompR numbers in the kidneys. On the contrary, at the fifth day post-infection, viable ΔompR bacteria were more drastically reduced in the kidneys than in the bladder compared with WT bacteria. Again, complementation of ΔompR bacteria successfully restored the viable counts to WT levels [33]. These studies demonstrate the relevant role played by the response regulator OmpR in promoting UPEC ascension along the urinary tract. Furthermore, these data are in agreement with those of other papers, where mutations in ompR were linked with changes in the E. coli outer-membrane-protein profile and with the notion that OmpR regulates iron acquisition [34] and induces the expression of the IutA protein, both critical for UPEC survival in the urinary tract [35][36].
The TCS KguS/KguR is another signaling pathway that is present in UPEC strains and absent in commensal and diarrheagenic E. coli, suggesting its contribution to UTI [37]. The role of this two-component regulatory system has been first investigated in vivo, by analyzing the ability of ΔkguS/kguR double-deleted strains to colonize the mouse urinary tract. Indeed, the absence of this TCS negatively impacts on colonization of the bladder and kidneys. The analysis of genes targeted by the KguS/KguR system was performed by growing bacteria in human urine to simulate the urinary tract environment. The differentially expressed proteins were grouped into three main categories on the basis of their functions: metabolism, cell envelope constituents, and translational machinery. A xylose isomerase and several outer membrane proteins were found to be overexpressed in a ΔkguR mutant strain, revealing the pleiotropic functions of this TCS. Furthermore, under different growth conditions, constitutive expression of kguR induces the over-expression of the c5035 gene that belongs to a genomic island (c5032-5039) strongly associated with the majority of UPEC strains [37]. Since that UPEC in vivo fitness is impaired when mice are infected with Δc5032-5039 bacteria, researchers have hypothesized that the described TCS may favor UPEC virulence through the regulation of c5032–5039 genes. Indeed, activation of the KguS/KguR regulatory system occurs under anaerobic conditions and is induced by α-ketoglutarate (α-KG) that is converted by a dehydrogenase to succinyl-CoA, which is further transformed to succinate by succinyl-CoA synthetase. In E. coli, α-KG is the only five-carbon (C5) dicarboxylate used as an intermediate in the citric acid/tricarboxylic acid (TCA) cycle, a fundamental process for the supply of metabolic intermediates and energy in catabolic and anabolic reactions [37]. Therefore, sensing external α-KG might represent an outstanding and unique strategy for UPEC to activate pathogenic mechanisms in anaerobic niches, given the absence of a functional α-KG dehydrogenase in all E. coli. Indeed, in the kidney, proximal tubule cells produce greater quantities of α-KG compared to any other cell type [38], suggesting a role of the KguS/KguR TCS in increasing UPEC fitness during in vivo infection. Moreover, deletion of the histidine kinase determines the downregulation of several genes belonging to the c5032-5039 genomic island in the presence of α-KG, underlying the importance of phosphorylation of the response regulator KguR.
As mentioned above, a major property of UPEC is to adhere to and invade urothelial cells where it can replicate inside the cytoplasm, forming highly proliferative intracellular communities that rapidly detach and infect neighboring epithelial cells [39][40]. In order to reduce bacterial colonization, the host accelerates exfoliation of the superficial layer of the urothelium, which however carries a risk of promoting bacterial dissemination. This may lead to the onset of chronic cystitis or the establishment of intracellular bacterial reservoirs [19][22][41].
Almost half of pathogenic E. coli strains isolated by patients with UTI expresses an α-hemolysin (HlyA), mainly involved in in vivo urothelial damage [42][43]. Moreover, HlyA lyses several mammalian cells after its assembly into a water-filled channel that perforates the cell membrane [4][44][45]. It also negatively modifies the cell–cell and cell–matrix interactions promoting exfoliation [46]. Notably, HlyA expression is directly down-regulated by a TCS named CpxRA [47][48][49], that is critical for enhancing UPEC infection in the urinary tract. The CpxRA TCS is composed of an inner membrane sensor with a histidine kinase activity, named CpxA, and of CpxR, the cytoplasmic response regulator. When the bacterial envelope is subjected to stress, CpxA autophosphorylates and, in turn, phosphorylates CpxR which can regulate gene expression. In addition to HlyA downregulation, CpxR is involved in the control protein folding, reduction of envelope stress [50][51], regulation of biofilm assembly [52][53] promotion of bacterial adherence [12] and motility [47][54], and activation of secretion systems [55]. The CpxRA TCS is known to induce the expression of CpxP, a small periplasmic protein that can inactivate the sensor kinase CpxA [56][57]. In addition, CpxP also interacts with unfolded proteins that are subsequently degraded by the protease DegP in order to control incorrect activation of CpxA in the absence of envelope stress [58].
In a mouse model of transurethral infection, viable ΔcpxRA bacteria were reduced in number compared with the WT UTI189 strain [59]. In contrast, absence of CpxP had no effect on in vivo infection. Furthermore, in vitro exposure to molecules inducing generalized stress, such as reactive nitrogen and oxygen radicals or factors damaging the bacterial membrane, did not affect the growth of ΔcpxRA and ΔcpxP bacteria, underlying how the environmental stress sensed by CpxA is specifically associated with in vivo infection. Nagamatsu K. et al. [60] have found that the human cystitis isolate UTI189 deleted for the response regulator CpxR (ΔcpxR) is more hemolytic than its wild-type parental strain due to increased HlyA expression and that the recombinant CpxR protein interacts with the hlyA promoter in an electrophoretic mobility shift assay (EMSA). By investigating in vivo bladder colonization by UPEC, it was possible to evidence a direct correlation between the CpxRA function, HlyA production, and exfoliation of the urothelium. The bladder colonization rate at 16 h post infection was significantly reduced using the ΔcpxR strain or a strain overexpressing hylA (WT/phlyCABD), compared to WT, ΔhlyA, ΔcpxRΔhlyA, and complemented ΔcpxR strains [60]. This indicated that excessive production of the HlyA cytotoxin in the absence of a functional CpxRA TCS negatively impacts the ability of UPEC to colonize the bladder. To measure exfoliation in infected mouse bladders, an elegant approach is to observe the distribution and abundance of binucleated superficial facet cells by DAPI-staining of bladder preparations. Since superficial cells also express high amounts expression of uroplakin III, a marker of terminal differentiation, facet cell abundance can be estimated by uroplakin III quantification in homogenized mouse bladders [60]. By either method, marked reductions in facet urothelial cells were observed in bladders infected with ΔcpxR and WT/phlyCABD bacteria. Cellular exfoliation is a mechanism that, on the one hand, eliminates superficial infected urothelial cells and, on the other hand, exposes underlying layers of the urothelium to UPEC with a potentially increased risk of deeper bacterial invasion. For these reasons, it is important to understand the mechanism leading to death and exfoliation of urothelial cells and their significance in terms of host defenses. Exfoliation is governed by different pathways that often involves activation of the caspase family of cysteine proteases, as evidenced in models using Staphylococcus aureus infection [61]. In the paper by Nagamatsu et al. [60], it was found that HylA over-expression in ΔcpxR bacteria triggers, in human cultured urothelial cells, a proinflammatory form of cell death called pyroptosis, through activation of Caspase-1/Caspase-4 and release of IL-1α and IL-1β, as evidenced using chemical inhibitors or siRNA-mediated knockdown of Caspase-1, Caspase-4, and NLRP3. Indeed, these treatments determined a significant reduction in the release of cytoplasmatic lactate dehydrogenase (LDH), IL-1α, and IL-1β from urothelial cells infected with UPEC ΔcpxR and WT/phlyCABD strains [60]. Furthermore, fluorescence microscopy revealed the activation of Caspase-1/Caspase-4 as HylA-overexpressing bacteria were surrounded by visible speckles which, conversely, were not visible in ΔhlyA or ΔcpxRΔhlyA-infected cells. These results were also confirmed in the in vivo UTI model by increased expression of mCasp11, Nlrp3, Il1α, and Il1β genes and cleaved Caspase-1 in bladders of mice infected with ΔcpxR bacteria [60]. Administration of a Caspase-1/mCaspase-11 inhibitor to mice infected with the ΔcpxR strain restored acute virulence of this mutant to WT levels, concomitantly with a reduction of epithelial exfoliation and inflammatory infiltrates [60]. Collectively, these data show that downregulation of hylA expression by the CpxRA TCS is fundamental for UPEC to evade host defenses associated with pyroptotic cell death, increased exfoliation, and induction of inflammatory responses.
The E. coli BarA-UvrY TCS has been previously described as a signaling mechanism used to withstand osmotic stress, as shown using barA mutants [62][63]. In addition, the BarA-UvrY system regulates expression of the csrA gene, whose product controls flagellar assembly, carbon metabolism, and biofilm formation [62][63][64][65][66]. In mouse models of ascending UTI, it has been shown that bacteria devoid of barA are impaired in their ability to colonize the bladder and the kidneys [67]. Similarly, uvrY-deleted UPEC were impaired in their ability to colonize the mouse bladder and invade urothelial cells in vitro [67]. Furthermore, when this TCS is active, cytotoxicity for human kidney cells is augmented, as exemplified by observations that supernatants from the uvrY-deleted strain are unable to affect cell viability. Conversely, the effects of barA mutation are not as evident as those described for uvrY in this system [67].

2. Pseudomonas aeruginosa

Pseudomonas aeruginosa is an opportunistic pathogen that is the third most common cause of UTI. These infections can be acute or chronic and is often difficult to eradicate because of antibiotic resistance. Acute infections are often characterized by a rapid progression [68], while chronic infections appear to be associated with slower bacterial growth, biofilm formation, and antibiotic resistance [69]. Furthermore, this microorganism is linked to infections in immunocompromised patients [70][71]. A multitude of virulence factors, particularly those associated with bacterial colonization and tissue invasion, play important roles in the pathogenesis of P. aeruginosa UTI. The main P. aeruginosa extracellular appendages are fimbriae and pili that are required for the initial adhesion to host surfaces [72][73], while polysaccharides are involved in maintenance of bacterial communities, including biofilm formation [73][74]. The genome of P. aeruginosa contains numerous TCSs which allow bacteria to recognize and respond to environmental signals in a highly complex manner. The best studied TCSs in the context of P. aeruginosa pathogenesis are associated with biofilm formation, motility, and production of cytotoxins such as pyocyanin [75].
Biofilms are complex communities of bacterial cells enclosed in an extracellular matrix composed of lipids, polysaccharides, and extracellular DNA (eDNA) [76]. Biofilm assembly is the result of important stages involving reversible attachment, irreversible adherence to surfaces, microcolony formation, maturation, and dispersion. P. aeruginosa produces robust biofilms on the surface of human tissues and implanted devices and extracellular polysaccharides, such as Pel, Psl, and alginate, are of major importance in the formation and stability of a microbial biofilm community. Biofilm formation enables the pathogen to become tightly associated with a favorable habitat and to further evade the host immune attack [77]. In UTI, such as CAUTI, biofilms formed by P. aeruginosa seem not to require alginate. A model has been proposed whereby pyocyanin, a secreted virulence factor, may promote biofilm formation by increasing the viscosity of eDNA [78].
In this context, TCSs control the change from a planktonic to a sessile lifestyle and vice versa in response to external stimuli by differently regulating the expression of several virulence genes. The initial attachment of bacteria to biotic or abiotic surfaces is an important step in biofilm assembly, in which several surface-exposed components, such as flagella, type IV pili and fimbriae, are involved. The TCS PilSR regulates, for example, type IV pilus expression [79], while the FleSR TCS controls the formation of flagella, which increase the hydrophobicity of the bacterial surface and facilitate reversible binding to abiotic surfaces [80]. An additional TCS involved in the initial phases of P. aeruginosa biofilm formation is the Roc system, where RocS1 and RocA1 are sensor HK and RR, respectively. The Roc system favors the expression of cupB and cupC gene clusters, each containing a minimal set of genes required for the expression of adhesive fimbrial organelles belonging to the chaperone/usher family [81]. The BfiSR TCS is, instead, involved in the bacterial irreversible attachment through transcriptional regulation of the RNase G, which modulates the levels of a small RNA (rsmZ), belonging to a well-characterized small RNA-based regulatory system [82]. The KinB-AlgB TCS (in which KinB is the HK and AlgB the transcriptional activator) is involved in the direct regulation of algD [83], a gene required for alginate biosynthesis and in the onset of mucoid phenotypes as suggested by acute pneumonia murine models [84]. Moreover, an AlgB-independent role of KinB has been demonstrated in models of acute infections in zebrafish embryos [85]. BfmR is a response regulator that modulates the release of eDNA, which is required for biofilm maturation and integrity [86] and the deletion of its cognate sensor regulator BfmS causes a significant reduction of the recovered bacteria from infected murine lungs [87]. The high rate of BfmR phosphorylation and enhanced chronic infection state has been further linked to single point mutations found in the sensor BfmS of clinical isolates [88]. PprAB, another important TCS, controls the expression of the cupE gene cluster responsible for the regulation of cell-to-cell connections not only during microcolony formation but also in the final maturation of biofilms [89]. Finally, modulation of rhamnolipids and other signaling molecules is associated with the ability of the TCS BqsSR to promote biofilm dispersal, as assessed by experimental approaches performed with ΔbqsS and ΔbqsR bacteria [90]. In the context of UTI, rhamnolipid expression is upregulated under the iron-limiting conditions of the urinary tract, enabling P. aeruginosa ascension and persistence [91].
P. aeruginosa uses three different types of motility to colonize the host: swimming, swarming, and twitching. The role of P. aeruginosa motility in UTI is not clear. A report dealing with a limited number of isolates showed an increased bacterial ability to swarm in UTI compared to CAUTI, whereas in the context of CAUTI, swarming was lower in chronic conditions compared to acute ones [92]. The swimming process involves the rotation of a single flagellum, while swarming requires intercellular coordination among bacteria to progress on surfaces, and twitching involves continuous length changes of type IV pili. Several TCSs have been also described referring to motility. The FleSR TCS governs flagellar biosynthesis while the GacSA system works together with other membrane sensors to finely regulate sRNAs associated with intracellular signals triggering in acute infection [80][93]. Other studies demonstrated how the CarSR regulatory system regulates swarming motility by sensing external Ca2+ concentrations [94] and how PilSR is responsible of pilus- and flagellum-dependent swimming motility [79]. In contrast to flagella, type IV pili are used by P. aeruginosa to move by alternating ATP-dependent elongation and retraction phases [95]. The FimS-AlgR, for example, controls the twitching motility by enhancing the expression of genes involved in pili assembly [96], whereas phosphorylation of the response regulator PilG is useful to facilitate pilus extension [97].
P. aeruginosa produces pyocyanin whose cytotoxic effects have been well characterized [98]. Pyocyanin production is regulated by several Quorum Sensing (QS) systems, but the role played by TCSs is also crucial. The association of GacSA with the sensors LadS and RetS is important in the expression of phz operons encoding for the pyocyanin precursors such as chorismic acid [99]. The BqsSR system positively regulates the 2-heptyl-3-hydroxy-4-quinolone (PQS) that is essential for pyocyanin production [90], whereas a non-functional BqsSR system decreases pyocyanin synthesis [90]. The AlgZR TCS regulates indirectly pyocyanin production through the repressor CzcR and an interesting role has been ascribed to phosphorylation of the regulator AlgZR in acute murine wound and pneumonia models of infections [100].
In the course of pathogenesis, P. aeruginosa secretes numerous toxins and hydrolytic enzymes through different types of secretion systems. Secretion system type II and III are the most important. The type II system favors the secretion of the chitin-binding protein E and D (CbpE and CbpD, respectively), elastase or exotoxin A (also named as ToxA) [101][102]. Conversely, the type III system promotes the secretion of ExoS, ExoT, ExoU, and ExoU by playing, in this manner, a relevant role in host damage and immune response dysfunction. Clinical P. aeruginosa isolates from UTI have revealed higher levels of ExoS compared to tracheal isolates [103]. The GtrS-GltR TCS is engaged in ToxA production [104] and gtrS mutant bacteria are unable to greatly infect murine lungs [105], while the GacSA system controls elastase and type III secretion systems [106]. Moreover, the Roc system is involved in the production of ExoY and ExoT toxins [106], compared to CbrAB that determines the synthesis also of ExoS toxin [107]. Furthermore, the role of the sensor kinase CbrA has been investigated in murine peritoneal and lung infection models by showing a loss of virulence for cbrA mutant and ruling out the involvement of alterations in bacterial motility, biofilm formation, and cytotoxicity [108]. Contrarily, the FimS-AlgR system negatively regulates type III secretion [109].
Antimicrobial resistance is not only associated with both biofilm formation, but also intracellular persistence [110]. It has been demonstrated that P. aeruginosa can survive inside human bladder epithelial cells and stably reside in intracellular reservoirs by means of the two-component regulator AlgZR [111]. As mentioned above, AlgR is an important virulence factor regulator, controlling type IV pilus-dependent twitching motility and alginate production (via regulation of algC and algD promoters). It also negatively regulates biofilm formation, quorum sensing, and anaerobic metabolism [112]. Both laboratory and clinical strains were found to remain alive intracellularly for up to 48 h, as shown by gentamicin protection assays and by confocal imaging revealing Pseudomonas aeruginosa co-localization with the intracellular marker of endocytosis LAMP-1 [111]. Deletion of the algR gene is associated with decreased intracellular survival, compared to WT bacteria. Like other two-component response regulators [113], AlgR is activated after being phosphorylated by the histidine kinase AlgZ (or FimS) [112]. Deletion of algZ results in reduced invasion and intracellular survival, suggesting that phosphorylation of AlgR might be involved in these phenomena. An interesting mutational approach to investigate the activation of a response regulator by its cognate histidine kinase is to create a single point mutation in the predicted RR phosphorylation site. Mutants with a non-phosphorylated (D54N) form of AlgR (AlgR phosphoablative, locked into the constitutive, non-activated state) were defective in bladder cell invasion, while a phosphomimetic (D54E) mutant locked into the activated state invaded cells similarly as WT bacteria [111].
Bacterial adaptation to the intracellular host environment is associated with transcriptional changes that can be studied in depth by using transcriptomic, or RNA-seq, analysis [114], although it is not always technically easy to recover sufficient amounts of bacterial RNA for this kind of studies. After invasion of bladder epithelial cells, wild-type bacteria upregulate genes encoding virulence factors, such as the type III secretion system and iron acquisition proteins such as pyocyanin and pyoverdin [115][116], while downregulate genes related to arginine catabolism and lipopolysaccharide synthesis, which were previously found to be overexpressed by extracellular bacteria in a murine pneumonia model [116]. Conversely, by comparing transcriptional profiles of WT and ΔalgR bacteria, seven genes involved in protein translation and in transmembrane protein synthesis were shown to be downregulated in the ΔalgR strain. Moreover, low amounts of ribosomal RNA (rRNA) were detected in the ΔalgR strain, suggesting that even in the first stages of P. aeruginosa internalization into bladder cells, bacteria without the response regulator AlgR may be incapable of surviving in the intracellular compartments because of deficiencies in their translational machinery [111].
On the other hand, in the course of bacterial infection, the host changes its transcriptional activity to counteract the invading pathogen. In light of this, information on the host, in addition to the pathogen, transcriptional responses may be useful to understand the mechanisms of intracellular infection by P. aeruginosa. Dual RNA-seq studies indicated that activation of NF-κB-dependent genes in bladder epithelial cells is exploited by P. aeruginosa to survive intracellularly [111]. For example, blockade of NF-κB signaling with chemical inhibitors reduced intracellular survival of wild-type P. aeruginosa. NF-κB-dependent bacterial survival in bladder cells is paradoxical, since the same NF-κB pathway was previously found to be required for inflammatory responses and clearance of extracellular P. aeruginosa in a pneumonia model [116].
To study the role of the AlgZR TCS in vivo, mice were transurethrally infected with P. aeruginosa and bladders were harvested to measure colony forming units (CFU). After 2 h of infection, a high number of WT bacteria was recovered intracellularly and was found to persist for up to 7 days in almost all infected mice. On the contrary, deletion of algR resulted in low and transient intracellular bacterial burden in the bladder [111].
In light of these data, the authors went on to demonstrate that P. aeruginosa survival inside epithelial cells contributes to the onset and recurrence of chronic infection. Furthermore, persistent infections by uropathogens are strictly related to antibiotic resistance [117] and, in the case of P. aeruginosa, the discovery of therapies targeting the host inflammatory pathways such as NF-κB signaling could be an intriguing approach to control infections of the urinary tract.

3. Enterococcus faecalis

Enterococcus faecalis is a Gram-positive bacterium responsible for CAUTI. Implantation of a urinary catheter in the bladder evokes histological changes [118], inflammation [119], and the release of fibrinogen which coats the catheter [120]. Binding to the extracellular matrix has been described for different enterococcal proteins, such as Ace (adhesin of collagen from enterococci) and E. faecalis surface proteins (Fss). While Ace binds to collagen types I and IV, laminin, and dentin [121][122], Fss proteins bind to fibrinogen [123]. Recent studies demonstrated that enterococcal membrane glycolipids recognize the glycosaminoglycans heparin and heparan sulfate present on human colonic cells to mediate bacterial adhesion to host tissues [124]. E. faecalis harbors two pilin gene clusters (PGCs), named ebp locus (standing for endocarditis and biofilm-associated pili) [125] and the bee locus (biofilm enhancer in enterococci) [126], both contributing to the pathogenesis of endocarditis and urinary tract infection. Esp proteins facilitate the E. faecalis adherence to fibrinogen and collagen receptors present in bladder cells in the mouse model. In addition, in vivo studies show that Ebp regulate the biofilm formation during CAUTI [127]. Gelatinase is, instead, a protease used by E. faecalis to control biofilm formation and its expression is increased by the fsr TCS which is composed of four genes (fsrA, fsrB, fsrD, and fsrC) [128]. This system is activated in response to a peptide lactone, which is encoded by fsrD [128]. As far as we know, the two-component regulatory system GrvRS, which directly controls ace transcription [129], is the only one to have been investigated in UTI. Bacteria deleted for grvR (ΔgrvR) are impaired in their ability to colonize the urinary tract and, conversely, complementation of ΔgrvR restores in vivo virulence. Moreover, the absence of GrvR determines a reduction in binding to Ace extracellular matrix targets and biofilm formation.

4. Streptococcus agalactiae

Group B streptococcus (or GBS) is a Gram-positive commensal of the human gastrointestinal and genital tract flora in almost 30% of healthy women [130][131]. This bacterium is one of the leading causes of infection in newborns [132] and adults with chronic pathologies [133]. It can cause sepsis and meningitis in neonates after infection in utero or during passage through the birth canal in the first week of life (early onset disease). Neonates can also acquire infection at later times and develop late-onset disease, predominantly associated with meningitis. In addition to neonatal infection and sepsis in adults, this pathogen can be also responsible for UTI, accounting for approximately 2–3% of all UTI [134][135]. GBS UTI includes asymptomatic bacteriuria (ABU), cystitis, pyelonephritis, and urosepsis [136][137]. Furthermore, GBS UTI during pregnancy carries a high risk of chorioamnionitis and premature labor [138][139]. While the actual prevalence of GBS UTI is uncertain, GBS ABU detected during pregnancy is a clear indication of maternal genital tract colonization [139][140]. Indeed, GBS ABU has been associated with a high risk for early-onset disease (EOD) in newborns [139][141] and, for this reason, must be taken into consideration for intrapartum antibiotic chemoprophylaxis in conjunction with other factors [142]. In contrast to other pathological conditions caused by GBS, the clinical and molecular mechanisms of GBS UTI are not well understood. Some studies have shown that the secretion of inflammatory mediators, in mouse models of transurethral infection is induced during serotype III GBS strains infection [135][143][144], but only few studies have described the role played by known GBS-virulence factors in this context. For example, sialic-acid residues of the capsular polysaccharide are likely to play a role for infection of the urinary tract [142][145], whereas β-hemolysin/cytolysin (β-h/c) can elicit a strong neutrophil response in the murine bladder because of its cytotoxic effect on uroepithelial cells [146].
One of the most studied TCS in GBS is the CovRS regulatory system where the sensor histidine kinase CovS senses external signals and activates the response regulator CovR [147]. This system directly or indirectly regulates the expression of different genes [148], including those encoding virulence factors, such as β-hemolysin/cytolysin (β-h/c) [149], HvgA [150], PbsP [151][152][153][154], and other ones. Furthermore, pbsP is subjected to the transcriptional regulation mediated by the recently discovered SaeRS TCS that greatly enhances its expression by rendering GBS more virulent in vivo [155]. Studies on SaeRS correlation with pbsP are currently underway among different clonotypes and in other in vivo infection models, given the importance of this adhesin in GBS pathogenesis [151][152][153][154].
CovR is particularly involved in favoring the transition from commensalism to virulence by controlling the expression of more than 150 genes. Until now, only a paper briefly describes the in vivo contribution of this TCS to the onset of UTI [156]. Infection assays using a covR-deficient mutant demonstrate significant attenuation in the ability of GBS to colonize the bladder and urine in a mouse model. Furthermore, the levels of pro-inflammatory cytokines, such as interleukin 6, 17A, 12, and chemokines, are lower in response to bacteria lacking CovR compared with the WT strain upon bladder infection. In contrast, other innate immune mediators are equally overexpressed by both WT and covR-deficient strains. In vitro experiments on bladder cells corroborate the idea that CovR is involved in cellular adhesion and invasion and in acute GBS-induced cytotoxicity. Indeed, fluorescence images revealed co-localization of ΔcovR bacteria and Caspase 3 (an executioner of apoptosis), a feature that correlates with the hyper-hemolytic phenotype of the mutant strain. This observation is in line with the described role of β-h/c in S. agalactiae UTI [146]. As a pathogenic strategy, GBS is able to alter the expression of CovR in vivo to finely modulate virulence genes expression on the basis of the host niches encountered [157]. This CovR properties are in line with other in vivo models of GBS infection. For instance, in murine sepsis models, the absence of CovR results in the recovery of increased numbers of bacteria in infected brains [158]. Moreover, covR-deficient bacteria are less invasive in human vaginal epithelial cells [159].

5. Proteus Mirabilis

Proteus mirabilis is a leading cause of pyelonephritis, urolithiasis and is, particularly, associated with long-term catheterization [160][161]. Proteus has several virulence factors such as fimbriae or appendages mediating adherence to cells of the urinary tract and also to catheters [162][163][164]. Furthermore, this pathogen produces urease that uses ammonia as substrate by increasing pH with the subsequent precipitation of calcium and magnesium ions and the formation of urinary stones that can reduce urinary flow with consequent tissue damage [165][166]. The precipitation of minerals may further promote bacterial adherence to the catheter, laying the foundations for biofilm formation [167][168]. Subsequently, bacteria embedded in urinary stones may evade the host immune response and/or the efficacy of antibiotics [169]. These conclusions were reached using a mouse model of UTI where the absence of the gene encoding for urease significantly decreased the number of recovered bacteria from kidney and bladder [170]. P. mirabilis migrates along catheters by means of a swarming process to migrate along the urinary tract [171][172], even though non-swarming mutants progress only on latex catheters coated with hydrogels [173]. Moreover, in P. mirabilis biofilms, swarm cells have been observed and proposed as mediators of bacterial dispersal from catheter to the urinary tract [174]. As far as we know, few TCSs have been characterized in P. mirabilis, but not in the context of murine urinary tract models of infection. The RppAB TCS regulates the synthesis of LPS and flagella. RppA is, indeed, a regulator of arnA gene that encodes for a bacterial decarboxylase useful for LPS modification [175]. A mutated rppA gene is also linked to a more evident swarming phenotype [176]. Another recent paper has also highlighted the role played by the QseEF TCS in modulating swarming motility. In general, the activated sensor kinase QseE determines the phosphorylation of the regulator QseF that, in turn, activates the expression of GlmY together with CheA and RcsB, two antagonist regulators of flagellum production [177]. A recent case report has described evidence of acquisition of resistance to imipenem and amikacin in a Proteus mirabilis clinical isolate, not previously showing this feature. Sequencing revealed the appearance of a point mutation (His-208-Pro) in the HAMP domain of the CpxA sensor [178]. This observation is in line with that seen in the CpxA of other microorganisms revealing resistance to β-lactams and major expression of efflux pump [179] by indicating how relevant is the role played by TCS in antibiotic resistance [180].

This entry is adapted from the peer-reviewed paper 10.3390/pathogens12010119

References

  1. Dhakal, B.K.; Kulesus, R.R.; Mulvey, M.A. Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli. Eur. J. Clin. Investig. 2008, 38 (Suppl. S2), 2–11.
  2. Russo, T.A.; Johnson, J.R. Medical and economic impact of extraintestinal infections due to Escherichia coli: Focus on an increasingly important endemic problem. Microbes Infect. 2003, 5, 449–456.
  3. Lane, M.C.; Alteri, C.J.; Smith, S.N.; Mobley, H.L. Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc. Natl. Acad. Sci. USA 2007, 104, 16669–16674.
  4. Dhakal, B.K.; Mulvey, M.A. The UPEC pore-forming toxin α-hemolysin triggers proteolysis of host proteins to disrupt cell adhesion, inflammatory, and survival pathways. Cell Host Microbe 2012, 11, 58–69.
  5. Connell, I.; Agace, W.; Klemm, P.; Schembri, M.; Mărild, S.; Svanborg, C. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc. Natl. Acad. Sci. USA 1996, 93, 9827–9832.
  6. Bien, J.; Sokolova, O.; Bozko, P. Role of Uropathogenic Escherichia coli Virulence Factors in Development of Urinary Tract Infection and Kidney Damage. Int. J. Nephrol. 2012, 2012, 681473.
  7. Hurst, R.E. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J. Urol. 1994, 12, 3–10.
  8. Parsons, C.L.; Greenspan, C.; Moore, S.W.; Mulholland, S.G. Role of surface mucin in primary antibacterial defense of bladder. Urology 1977, 9, 48–52.
  9. Floyd, K.A.; Moore, J.L.; Eberly, A.R.; Good, J.A.; Shaffer, C.L.; Zaver, H.; Almqvist, F.; Skaar, E.P.; Caprioli, R.M.; Hadjifrangiskou, M. Adhesive fiber stratification in uropathogenic Escherichia coli biofilms unveils oxygen-mediated control of type 1 pili. PLoS Pathog. 2015, 11, e1004697.
  10. Allsopp, L.P.; Beloin, C.; Ulett, G.C.; Valle, J.; Totsika, M.; Sherlock, O.; Ghigo, J.-M.; Schembri, M. Molecular characterization of UpaB and UpaC, two new autotransporter proteins of uropathogenic Escherichia coli CFT073. Infect. Immun. 2012, 80, 321–332.
  11. Valle, J.; Mabbett, A.N.; Ulett, G.C.; Toledo-Arana, A.; Wecker, K.; Totsika, M.; Schembri, M.; Ghigo, J.-M.; Beloin, C. UpaG, a new member of the trimeric autotransporter family of adhesins in uropathogenic Escherichia coli. J. Bacteriol. 2008, 190, 4147–4161.
  12. Hung, C.; Zhou, Y.; Pinkner, J.S.; Dodson, K.W.; Crowley, J.R.; Heuser, J.; Chapman, M.R.; Hadjifrangiskou, M.; Henderson, J.P.; Hultgren, S.J. Escherichia coli biofilms have an organized and complex extracellular matrix structure. mBio 2013, 4, e00645-13.
  13. Plançon, L.; Du Merle, L.; Le Friec, S.; Gounon, P.; Jouve, M.; Guignot, J.; Servin, A.; Le Bouguénec, C. Recognition of the cellular beta1-chain integrin by the bacterial AfaD invasin is implicated in the internalization of afa-expressing pathogenic Escherichia coli strains. Cell Microbiol. 2003, 5, 681–693.
  14. Li, K.; Feito, M.J.; Sacks, S.H.; Sheerin, N.S. CD46 (membrane cofactor protein) acts as a human epithelial cell receptor for internalization of opsonized uropathogenic Escherichia coli. J. Immunol. 2006, 177, 2543–2551.
  15. Rana, T.; Hasan, R.J.; Nowicki, S.; Venkatarajan, M.S.; Singh, R.; Urvil, P.T.; Popov, V.; Braun, W.; Popik, W.; Goodwin, S.; et al. Complement protective epitopes and CD55-microtubule complexes facilitate the invasion and intracellular persistence of uropathogenic Escherichia coli. J. Infect. Dis. 2014, 209, 1066–1076.
  16. Bens, M.; Vimont, S.; Ben Mkaddem, S.; Chassin, C.; Goujon, J.M.; Balloy, V.; Chignard, M.; Werts, C.; Vandewalle, A. Flagellin/TLR5 signalling activates renal collecting duct cells and facilitates invasion and cellular translocation of uropathogenic Escherichia coli. Cell Microbiol. 2014, 16, 1503–1517.
  17. Martinez, J.J.; Mulvey, M.A.; Schilling, J.D.; Pinkner, J.S.; Hultgren, S.J. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J. 2000, 19, 2803–2812.
  18. Bishop, B.L.; Duncan, M.J.; Song, J.; Li, G.; Zaas, D.; Abraham, S.N. Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells. Nat. Med. 2007, 13, 625–630.
  19. Mulvey, M.A.; Schilling, J.D.; Hultgren, S.J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect. Immun. 2001, 69, 4572–4579.
  20. Justice, S.S.; Hung, C.; Theriot, J.A.; Fletcher, D.A.; Anderson, G.G.; Footer, M.J.; Hultgren, S.J. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc. Natl. Acad. Sci. USA 2004, 101, 1333–1338.
  21. Eto, D.S.; Sundsbak, J.L.; Mulvey, M.A. Actin-gated intracellular growth and resurgence of uropathogenic Escherichia coli. Cell Microbiol. 2006, 8, 704–717.
  22. Mysorekar, I.U.; Hultgren, S.J. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc. Natl. Acad. Sci. USA 2006, 103, 14170–14175.
  23. Blango, M.G.; Mulvey, M.A. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob. Agents Chemother. 2010, 54, 1855–1863.
  24. Sarshar, M.; Scribano, D.; Limongi, D.; Zagaglia, C.; Palamara, A.T.; Ambrosi, C. Adaptive strategies of uropathogenic Escherichia coli CFT073: From growth in lab media to virulence during host cell adhesion. Int. Microbiol. 2022, 25, 481–494.
  25. Ambrosi, C.; Sarshar, M.; Aprea, M.R.; Pompilio, A.; Di Bonaventura, G.; Strati, F.; Pronio, A.; Nicoletti, M.; Zagaglia, C.; Palamara, A.T.; et al. Colonic adenoma-associated Escherichia coli express specific phenotypes. Microbes Infect. 2019, 21, 305–312.
  26. Sarshar, M.; Behzadi, P.; Ambrosi, C.; Zagaglia, C.; Palamara, A.T.; Scribano, D.; Fim, H.; Adhesive, A. Therapeutics: A Disarming Strategy Against Uropathogens. Antibiotics 2020, 9, 397.
  27. Scribano, D.; Sarshar, M.; Prezioso, C.; Lucarelli, M.; Angeloni, A.; Zagaglia, C.; Palamara, A.T.; Ambrosi, C. d-Mannose Treatment neither Affects Uropathogenic Escherichia coli Properties nor Induces Stable FimH Modifications. Molecules 2020, 25, 316.
  28. Withman, B.; Gunasekera, T.S.; Beesetty, P.; Agans, R.; Paliy, O. Transcriptional responses of uropathogenic Escherichia coli to increased environmental osmolality caused by salt or urea. Infect. Immun. 2013, 81, 80–89.
  29. Rentschler, A.E.; Lovrich, S.D.; Fitton, R.; Enos-Berlage, J.; Schwan, W.R. OmpR regulation of the uropathogenic Escherichia coli fimB gene in an acidic/high osmolality environment. Microbiology 2013, 159, 316–327.
  30. Igo, M.M.; Silhavy, T.J. EnvZ, a transmembrane environmental sensor of Escherichia coli K-12, is phosphorylated in vitro. J. Bacteriol. 1988, 170, 5971–5973.
  31. Cai, S.J.; Inouye, M. EnvZ-OmpR interaction and osmoregulation in Escherichia coli. J. Biol. Chem. 2002, 277, 24155–24161.
  32. Gally, D.L.; Leathart, J.; Blomfield, I.C. Interaction of FimB and FimE with the fim switch that controls the phase variation of type 1 fimbriae in Escherichia coli K-12. Mol. Microbiol. 1996, 21, 725–738.
  33. Schwan, W.R. Survival of uropathogenic Escherichia coli in the murine urinary tract is dependent on OmpR. Microbiology 2009, 155, 1832–1839.
  34. Gerken, H.; Vuong, P.; Soparkar, K.; Misra, R. Roles of the EnvZ/OmpR Two-Component System and Porins in Iron Acquisition in. mBio 2020, 11, e01192-20.
  35. Prohinar, P.; Forst, S.A.; Reed, D.; Mandic-Mulec, I.; Weiss, J. OmpR-dependent and OmpR-independent responses of Escherichia coli to sublethal attack by the neutrophil bactericidal/permeability increasing protein. Mol. Microbiol. 2002, 43, 1493–1504.
  36. Oshima, T.; Aiba, H.; Masuda, Y.; Kanaya, S.; Sugiura, M.; Wanner, B.L.; Mori, H.; Mizuno, T. Transcriptome analysis of all two-component regulatory system mutants of Escherichia coli K-12. Mol. Microbiol. 2002, 46, 281–291.
  37. Cai, W.; Wannemuehler, Y.; Dell’anna, G.; Nicholson, B.; Barbieri, N.L.; Kariyawasam, S.; Feng, Y.; Logue, C.; Nolan, L.; Li, G. A novel two-component signaling system facilitates uropathogenic Escherichia coli’s ability to exploit abundant host metabolites. PLoS Pathog. 2013, 9, e1003428.
  38. Pritchard, J.B. Intracellular alpha-ketoglutarate controls the efficacy of renal organic anion transport. J. Pharmacol. Exp. Ther. 1995, 274, 1278–1284.
  39. Flores-Mireles, A.L.; Walker, J.N.; Caparon, M.; Hultgren, S.J. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015, 13, 269–284.
  40. Berry, R.E.; Klumpp, D.J.; Schaeffer, A.J. Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli. Infect. Immun. 2009, 77, 2762–2772.
  41. Mulvey, M.A.; Schilling, J.D.; Martinez, J.J.; Hultgren, S.J. Bad bugs and beleaguered bladders: Interplay between uropathogenic Escherichia coli and innate host defenses. Proc. Natl. Acad. Sci. USA 2000, 97, 8829–8835.
  42. Smith, Y.C.; Rasmussen, S.B.; Grande, K.K.; Conran, R.M.; O’Brien, A.D. Hemolysin of uropathogenic Escherichia coli evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice. Infect. Immun. 2008, 76, 2978–2990.
  43. Ristow, L.C.; Welch, R.A. Hemolysin of uropathogenic Escherichia coli: A cloak or a dagger? Biochim. Biophys. Acta 2016, 1858, 538–545.
  44. Welch, R.A. Pore-forming cytolysins of gram-negative bacteria. Mol. Microbiol. 1991, 5, 521–528.
  45. Schwidder, M.; Heinisch, L.; Schmidt, H. Genetics, Toxicity, and Distribution of Enterohemorrhagic. Toxins 2019, 11, 502.
  46. Ma, Q.; Wood, T.K. OmpA influences Escherichia coli biofilm formation by repressing cellulose production through the CpxRA two-component system. Environ. Microbiol. 2009, 11, 2735–2746.
  47. De Wulf, P.; Kwon, O.; Lin, E.C. The CpxRA signal transduction system of Escherichia coli: Growth-related autoactivation and control of unanticipated target operons. J. Bacteriol. 1999, 181, 6772–6778.
  48. Weatherspoon-Griffin, N.; Zhao, G.; Kong, W.; Kong, Y.; Morigen Andrews-Polymenis, H.; McClelland, M.; Shi, Y. The CpxR/CpxA two-component system up-regulates two Tat-dependent peptidoglycan amidases to confer bacterial resistance to antimicrobial peptide. J. Biol. Chem. 2011, 286, 5529–5539.
  49. Mahoney, T.F.; Silhavy, T.J. The Cpx stress response confers resistance to some, but not all, bactericidal antibiotics. J. Bacteriol. 2013, 195, 1869–1874.
  50. Vogt, S.L.; Raivio, T.L. Just scratching the surface: An expanding view of the Cpx envelope stress response. FEMS Microbiol. Lett. 2012, 326, 2–11.
  51. Weber, R.F.; Silverman, P.M. The cpx proteins of Escherichia coli K12. Structure of the cpxA polypeptide as an inner membrane component. J. Mol. Biol. 1988, 203, 467–478.
  52. Prigent-Combaret, C.; Brombacher, E.; Vidal, O.; Ambert, A.; Lejeune, P.; Landini, P.; Dorel, C. Complex regulatory network controls initial adhesion and biofilm formation in Escherichia coli via regulation of the csgD gene. J. Bacteriol. 2001, 183, 7213–7223.
  53. Dorel, C.; Lejeune, P.; Rodrigue, A. The Cpx system of Escherichia coli, a strategic signaling pathway for confronting adverse conditions and for settling biofilm communities? Res. Microbiol. 2006, 157, 306–314.
  54. Inoue, T.; Shingaki, R.; Hirose, S.; Waki, K.; Mori, H.; Fukui, K. Genome-wide screening of genes required for swarming motility in Escherichia coli K-12. J. Bacteriol. 2007, 189, 950–957.
  55. Mitobe, J.; Arakawa, E.; Watanabe, H. A sensor of the two-component system CpxA affects expression of the type III secretion system through posttranscriptional processing of InvE. J. Bacteriol. 2005, 187, 107–113.
  56. Raivio, T.L.; Popkin, D.L.; Silhavy, T.J. The Cpx envelope stress response is controlled by amplification and feedback inhibition. J. Bacteriol. 1999, 181, 5263–5272.
  57. Hunke, S.; Keller, R.; Müller, V.S. Signal integration by the Cpx-envelope stress system. FEMS Microbiol. Lett. 2012, 326, 12–22.
  58. Buelow, D.R.; Raivio, T.L. Cpx signal transduction is influenced by a conserved N-terminal domain in the novel inhibitor CpxP and the periplasmic protease DegP. J. Bacteriol. 2005, 187, 6622–6630.
  59. Debnath, I.; Norton, J.P.; Barber, A.E.; Ott, E.M.; Dhakal, B.K.; Kulesus, R.R.; Mulvey, M.A. The Cpx stress response system potentiates the fitness and virulence of uropathogenic Escherichia coli. Infect. Immun. 2013, 81, 1450–1459.
  60. Nagamatsu, K.; Hannan, T.J.; Guest, R.L.; Kostakioti, M.; Hadjifrangiskou, M.; Binkley, J.; Dodson, K.; Raivio, T.; Hultgren, S. Dysregulation of Escherichia coli α-hemolysin expression alters the course of acute and persistent urinary tract infection. Proc. Natl. Acad. Sci. USA 2015, 112, E871–E880.
  61. Craven, R.R.; Gao, X.; Allen, I.C.; Gris, D.; Wardenburg, J.B.; McElvania-Tekippe, E.; Ting, J.; Duncan, J. Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS ONE 2009, 4, e7446.
  62. Mukhopadhyay, S.; Audia, J.P.; Roy, R.N.; Schellhorn, H.E. Transcriptional induction of the conserved alternative sigma factor RpoS in Escherichia coli is dependent on BarA, a probable two-component regulator. Mol. Microbiol. 2000, 37, 371–381.
  63. Mukhopadhyay, S.; Schellhorn, H.E. Identification and characterization of hydrogen peroxide-sensitive mutants of Escherichia coli: Genes that require OxyR for expression. J. Bacteriol. 1997, 179, 330–338.
  64. Suzuki, K.; Wang, X.; Weilbacher, T.; Pernestig, A.K.; Melefors, O.; Georgellis, D.; Babitzke, P.; Romeo, T. Regulatory circuitry of the CsrA/CsrB and BarA/UvrY systems of Escherichia coli. J. Bacteriol. 2002, 184, 5130–5140.
  65. Wei, B.L.; Brun-Zinkernagel, A.M.; Simecka, J.W.; Prüss, B.M.; Babitzke, P.; Romeo, T. Positive regulation of motility and flhDC expression by the RNA-binding protein CsrA of Escherichia coli. Mol. Microbiol. 2001, 40, 245–256.
  66. Jackson, D.W.; Suzuki, K.; Oakford, L.; Simecka, J.W.; Hart, M.E.; Romeo, T. Biofilm formation and dispersal under the influence of the global regulator CsrA of Escherichia coli. J. Bacteriol. 2002, 184, 290–301.
  67. Palaniyandi, S.; Mitra, A.; Herren, C.D.; Lockatell, C.V.; Johnson, D.E.; Zhu, X.; Mukhopadhyay, S. BarA-UvrY two-component system regulates virulence of uropathogenic E. coli CFT073. PLoS ONE 2012, 7, e31348.
  68. Bodey, G.P.; Bolivar, R.; Fainstein, V.; Jadeja, L. Infections caused by Pseudomonas aeruginosa. Rev. Infect. Dis. 1983, 5, 279–313.
  69. Gilligan, P.H. Microbiology of airway disease in patients with cystic fibrosis. Clin. Microbiol. Rev. 1991, 4, 35–51.
  70. Bodey, G.P. Pseudomonas aeruginosa infections in cancer patients: Have they gone away? Curr. Opin. Infect. Dis. 2001, 14, 403–407.
  71. Vidal, F.; Mensa, J.; Martínez, J.A.; Almela, M.; Marco, F.; Gatell, J.M.; Richart, C.; Soriano, E.; Jiménez de Anta, M.T. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Eur. J. Clin. Microbiol. Infect. Dis. 1999, 18, 473–477.
  72. Klausen, M.; Heydorn, A.; Ragas, P.; Lambertsen, L.; Aaes-Jørgensen, A.; Molin, S.; Tolker-Nielsen, T. Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants. Mol. Microbiol. 2003, 48, 1511–1524.
  73. Friedman, L.; Kolter, R. Two genetic loci produce distinct carbohydrate-rich structural components of the Pseudomonas aeruginosa biofilm matrix. J. Bacteriol. 2004, 186, 4457–4465.
  74. Branda, S.S.; Vik, S.; Friedman, L.; Kolter, R. Biofilms: The matrix revisited. Trends Microbiol. 2005, 13, 20–26.
  75. Francis, V.I.; Stevenson, E.C.; Porter, S.L. Two-component systems required for virulence in Pseudomonas aeruginosa. FEMS Microbiol. Lett. 2017, 364, fnx104.
  76. Thi, M.T.T.; Wibowo, D.; Rehm, B.H.A. Pseudomonas aeruginosa Biofilms. Int. J. Mol. Sci. 2020, 21, 8671.
  77. Maurice, N.M.; Bedi, B.; Sadikot, R.T. Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections. Am. J. Respir. Cell Mol. Biol. 2018, 58, 428–439.
  78. Cole, S.J.; Records, A.R.; Orr, M.W.; Linden, S.B.; Lee, V.T. Catheter-associated urinary tract infection by Pseudomonas aeruginosa is mediated by exopolysaccharide-independent biofilms. Infect. Immun. 2014, 82, 2048–2058.
  79. Kilmury, S.L.N.; Burrows, L.L. The Pseudomonas aeruginosa PilSR Two-Component System Regulates Both Twitching and Swimming Motilities. mBio 2018, 9, e01310-18.
  80. Dasgupta, N.; Wolfgang, M.C.; Goodman, A.L.; Arora, S.K.; Jyot, J.; Lory, S.; Ramphal, R. A four-tiered transcriptional regulatory circuit controls flagellar biogenesis in Pseudomonas aeruginosa. Mol. Microbiol. 2003, 50, 809–824.
  81. Kulasekara, H.D.; Ventre, I.; Kulasekara, B.R.; Lazdunski, A.; Filloux, A.; Lory, S. A novel two-component system controls the expression of Pseudomonas aeruginosa fimbrial cup genes. Mol. Microbiol. 2005, 55, 368–380.
  82. Goodman, A.L. Sit and stay a while: How BfiSR controls irreversible attachment in Pseudomonas aeruginosa biofilms. J. Bacteriol. 2010, 192, 5273–5274.
  83. Leech, A.J.; Sprinkle, A.; Wood, L.; Wozniak, D.J.; Ohman, D.E. The NtrC family regulator AlgB, which controls alginate biosynthesis in mucoid Pseudomonas aeruginosa, binds directly to the algD promoter. J. Bacteriol. 2008, 190, 581–589.
  84. Damron, F.H.; Owings, J.P.; Okkotsu, Y.; Varga, J.J.; Schurr, J.R.; Goldberg, J.B.; Schurr, M.J.; Yu, H.D. Analysis of the Pseudomonas aeruginosa regulon controlled by the sensor kinase KinB and sigma factor RpoN. J. Bacteriol. 2012, 194, 1317–1330.
  85. Chand, N.S.; Lee, J.S.; Clatworthy, A.E.; Golas, A.J.; Smith, R.S.; Hung, D.T. The sensor kinase KinB regulates virulence in acute Pseudomonas aeruginosa infection. J. Bacteriol. 2011, 193, 2989–2999.
  86. Petrova, O.E.; Schurr, J.R.; Schurr, M.J.; Sauer, K. The novel Pseudomonas aeruginosa two-component regulator BfmR controls bacteriophage-mediated lysis and DNA release during biofilm development through PhdA. Mol. Microbiol. 2011, 81, 767–783.
  87. Cao, Q.; Wang, Y.; Chen, F.; Xia, Y.; Lou, J.; Zhang, X.; Yang, N.; Sun, X.; Zhang, Q.; Zhuo, C.; et al. A novel signal transduction pathway that modulates rhl quorum sensing and bacterial virulence in Pseudomonas aeruginosa. PLoS Pathog. 2014, 10, e1004340.
  88. Cao, Q.; Yang, N.; Wang, Y.; Xu, C.; Zhang, X.; Fan, K.; Chen, F.; Liang, H.; Zhang, Y.; Deng, X.; et al. Mutation-induced remodeling of the BfmRS two-component system in Pseudomonas aeruginosa clinical isolates. Sci. Signal. 2020, 13, eaaz1529.
  89. Giraud, C.; Bernard, C.S.; Calderon, V.; Yang, L.; Filloux, A.; Molin, S.; Fichant, G.; Bordi, C.; de Bentzmann, S. The PprA-PprB two-component system activates CupE, the first non-archetypal Pseudomonas aeruginosa chaperone-usher pathway system assembling fimbriae. Environ. Microbiol. 2011, 13, 666–683.
  90. Dong, Y.H.; Zhang, X.F.; An, S.W.; Xu, J.L.; Zhang, L.H. A novel two-component system BqsS-BqsR modulates quorum sensing-dependent biofilm decay in Pseudomonas aeruginosa. Commun. Integr. Biol. 2008, 1, 88–96.
  91. Glick, R.; Gilmour, C.; Tremblay, J.; Satanower, S.; Avidan, O.; Déziel, E.; Greenberg, E.P.; Poole, K.; Banin, E. Increase in rhamnolipid synthesis under iron-limiting conditions influences surface motility and biofilm formation in Pseudomonas aeruginosa. J. Bacteriol. 2010, 192, 2973–2980.
  92. Tielen, P.; Narten, M.; Rosin, N.; Biegler, I.; Haddad, I.; Hogardt, M.; Neubauer, R.; Schobert, M.; Wiehlmann, L.; Jahn, D. Genotypic and phenotypic characterization of Pseudomonas aeruginosa isolates from urinary tract infections. Int. J. Med. Microbiol. 2011, 301, 282–292.
  93. Jimenez, P.N.; Koch, G.; Thompson, J.A.; Xavier, K.B.; Cool, R.H.; Quax, W.J. The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol. Mol. Biol. Rev. 2012, 76, 46–65.
  94. Guragain, M.; King, M.M.; Williamson, K.S.; Pérez-Osorio, A.C.; Akiyama, T.; Khanam, S.; Patrauchan, M.A.; Franklin, M.J. The Pseudomonas aeruginosa PAO1 Two-Component Regulator CarSR Regulates Calcium Homeostasis and Calcium-Induced Virulence Factor Production through Its Regulatory Targets CarO and CarP. J. Bacteriol. 2016, 198, 951–963.
  95. Hospenthal, M.; Costa, T.; Waksman, G.A. Comprehensive guide to pilus biogenesis in Gram-negative bacteria. Nat. Rev. Microbiol. 2017, 15, 365–379.
  96. Marko, V.A.; Kilmury, S.L.N.; MacNeil, L.T.; Burrows, L.L. Pseudomonas aeruginosa type IV minor pilins and PilY1 regulate virulence by modulating FimS-AlgR activity. PLoS Pathog. 2018, 14, e1007074.
  97. Bertrand, J.J.; West, J.T.; Engel, J.N. Genetic analysis of the regulation of type IV pilus function by the Chp chemosensory system of Pseudomonas aeruginosa. J. Bacteriol. 2010, 192, 994–1010.
  98. Britigan, B.E.; Roeder, T.L.; Rasmussen, G.T.; Shasby, D.M.; McCormick, M.L.; Cox, C.D. Interaction of the Pseudomonas aeruginosa secretory products pyocyanin and pyochelin generates hydroxyl radical and causes synergistic damage to endothelial cells. Implications for Pseudomonas-associated tissue injury. J. Clin. Investig. 1992, 90, 2187–2196.
  99. Mavrodi, D.V.; Bonsall, R.F.; Delaney, S.M.; Soule, M.J.; Phillips, G.; Thomashow, L.S. Functional analysis of genes for biosynthesis of pyocyanin and phenazine-1-carboxamide from Pseudomonas aeruginosa PAO1. J. Bacteriol. 2001, 183, 6454–6465.
  100. Okkotsu, Y.; Tieku, P.; Fitzsimmons, L.F.; Churchill, M.E.; Schurr, M.J. Pseudomonas aeruginosa AlgR phosphorylation modulates rhamnolipid production and motility. J. Bacteriol. 2013, 195, 5499–5515.
  101. Galloway, D.R. Pseudomonas aeruginosa elastase and elastolysis revisited: Recent developments. Mol. Microbiol. 1991, 5, 2315–2321.
  102. Foulkes, D.M.; McLean, K.; Haneef, A.S.; Fernig, D.G.; Winstanley, C.; Berry, N.; Kaye, S.B. Pseudomonas aeruginosa Toxin ExoU as a Therapeutic Target in the Treatment of Bacterial Infections. Microorganisms 2019, 7, 707.
  103. Woods, D.E.; Schaffer, M.S.; Rabin, H.R.; Campbell, G.D.; Sokol, P.A. Phenotypic comparison of Pseudomonas aeruginosa strains isolated from a variety of clinical sites. J. Clin. Microbiol. 1986, 24, 260–264.
  104. Daddaoua, A.; Molina-Santiago, C.; de la Torre, J.; Krell, T.; Ramos, J.L. GtrS and GltR form a two-component system: The central role of 2-ketogluconate in the expression of exotoxin A and glucose catabolic enzymes in Pseudomonas aeruginosa. Nucleic Acids Res. 2014, 42, 7654–7663.
  105. Xu, C.; Cao, Q.; Lan, L. Glucose-Binding of Periplasmic Protein GltB Activates GtrS-GltR Two-Component System in Pseudomonas aeruginosa. Microorganisms 2021, 9, 447.
  106. Sultan, M.; Arya, R.; Kim, K.K. Roles of Two-Component Systems in Pseudomonas aeruginosa Virulence. Int. J. Mol. Sci. 2021, 22, 1215.
  107. Yeung, A.T.; Bains, M.; Hancock, R.E. The sensor kinase CbrA is a global regulator that modulates metabolism, virulence, and antibiotic resistance in Pseudomonas aeruginosa. J. Bacteriol. 2011, 193, 918–931.
  108. Yeung, A.T.; Janot, L.; Pena, O.M.; Neidig, A.; Kukavica-Ibrulj, I.; Hilchie, A.; Levesque, R.C.; Overhage, J.; Hancock, R.E. Requirement of the Pseudomonas aeruginosa CbrA sensor kinase for full virulence in a murine acute lung infection model. Infect. Immun. 2014, 82, 1256–1267.
  109. Wu, W.; Badrane, H.; Arora, S.; Baker, H.V.; Jin, S. MucA-mediated coordination of type III secretion and alginate synthesis in Pseudomonas aeruginosa. J. Bacteriol. 2004, 186, 7575–7585.
  110. Pang, Z.; Raudonis, R.; Glick, B.R.; Lin, T.J.; Cheng, Z. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotechnol. Adv. 2019, 37, 177–192.
  111. Penaranda, C.; Chumbler, N.M.; Hung, D.T. Dual transcriptional analysis reveals adaptation of host and pathogen to intracellular survival of Pseudomonas aeruginosa associated with urinary tract infection. PLoS Pathog. 2021, 17, e1009534.
  112. Okkotsu, Y.; Little, A.S.; Schurr, M.J. The Pseudomonas aeruginosa AlgZR two-component system coordinates multiple phenotypes. Front. Cell. Infect. Microbiol. 2014, 4, 82.
  113. Stock, A.M.; Robinson, V.L.; Goudreau, P.N. Two-component signal transduction. Annu. Rev. Biochem. 2000, 69, 183–215.
  114. Westermann, A.J.; Barquist, L.; Vogel, J. Resolving host-pathogen interactions by dual RNA-seq. PLoS Pathog. 2017, 13, e1006033.
  115. Frisk, A.; Schurr, J.R.; Wang, G.; Bertucci, D.C.; Marrero, L.; Hwang, S.H.; Hassett, D.J.; Schurr, M.J. Transcriptome analysis of Pseudomonas aeruginosa after interaction with human airway epithelial cells. Infect. Immun. 2004, 72, 5433–5438.
  116. Damron, F.H.; Oglesby-Sherrouse, A.G.; Wilks, A.; Barbier, M. Dual-seq transcriptomics reveals the battle for iron during Pseudomonas aeruginosa acute murine pneumonia. Sci. Rep. 2016, 6, 39172.
  117. Bader, M.S.; Loeb, M.; Leto, D.; Brooks, A.A. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad. Med. 2020, 132, 234–250.
  118. Delnay, K.M.; Stonehill, W.H.; Goldman, H.; Jukkola, A.F.; Dmochowski, R.R. Bladder histological changes associated with chronic indwelling urinary catheter. J. Urol. 1999, 161, 1106–1108; discussion 8–9.
  119. Guiton, P.S.; Hannan, T.J.; Ford, B.; Caparon, M.G.; Hultgren, S.J. Enterococcus faecalis overcomes foreign body-mediated inflammation to establish urinary tract infections. Infect. Immun. 2013, 81, 329–339.
  120. Flores-Mireles, A.L.; Pinkner, J.S.; Caparon, M.G.; Hultgren, S.J. EbpA vaccine antibodies block binding of Enterococcus faecalis to fibrinogen to prevent catheter-associated bladder infection in mice. Sci. Transl. Med. 2014, 6, 254ra127.
  121. Kowalski, W.J.; Kasper, E.L.; Hatton, J.F.; Murray, B.E.; Nallapareddy, S.R.; Gillespie, M.J. Enterococcus faecalis adhesin, Ace, mediates attachment to particulate dentin. J. Endod. 2006, 32, 634–637.
  122. Nallapareddy, S.R.; Qin, X.; Weinstock, G.M.; Höök, M.; Murray, B.E. Enterococcus faecalis adhesin, ace, mediates attachment to extracellular matrix proteins collagen type IV and laminin as well as collagen type I. Infect. Immun. 2000, 68, 5218–5224.
  123. Sillanpää, J.; Nallapareddy, S.R.; Houston, J.; Ganesh, V.K.; Bourgogne, A.; Singh, K.V.; Murray, B.E.; Höök, M. A family of fibrinogen-binding MSCRAMMs from Enterococcus faecalis. Microbiol. 2009, 155, 2390–2400.
  124. Sava, I.G.; Zhang, F.; Toma, I.; Theilacker, C.; Li, B.; Baumert, T.F.; Holst, O.; Linhardt, R.J.; Huebner, J. Novel interactions of glycosaminoglycans and bacterial glycolipids mediate binding of enterococci to human cells. J. Biol. Chem. 2009, 284, 18194–18201.
  125. Cobo Molinos, A.; Abriouel, H.; Omar, N.B.; López, R.L.; Galvez, A. Detection of ebp (endocarditis- and biofilm-associated pilus) genes in enterococcal isolates from clinical and non-clinical origin. Int. J. Food Microbiol. 2008, 126, 123–126.
  126. Nallapareddy, S.R.; Singh, K.V.; Sillanpää, J.; Garsin, D.A.; Höök, M.; Erlandsen, S.L.; Murray, B.E. Endocarditis and biofilm-associated pili of Enterococcus faecalis. J. Clin. Investig. 2006, 116, 2799–2807.
  127. Guiton, P.S.; Hung, C.S.; Hancock, L.E.; Caparon, M.G.; Hultgren, S.J. Enterococcal biofilm formation and virulence in an optimized murine model of foreign body-associated urinary tract infections. Infect. Immun. 2010, 78, 4166–4175.
  128. Nakayama, J.; Chen, S.; Oyama, N.; Nishiguchi, K.; Azab, E.A.; Tanaka, E.; Kariyama, R.; Sonomoto, K. Revised model for Enterococcus faecalis fsr quorum-sensing system: The small open reading frame fsrD encodes the gelatinase biosynthesis-activating pheromone propeptide corresponding to staphylococcal agrd. J. Bacteriol. 2006, 188, 8321–8326.
  129. Roh, J.H.; Singh, K.V.; La Rosa, S.L.; Cohen, A.L.; Murray, B.E. The two-component system GrvRS (EtaRS) regulates ace expression in Enterococcus faecalis OG1RF. Infect. Immun. 2015, 83, 389–395.
  130. Campbell, J.R.; Hillier, S.L.; Krohn, M.A.; Ferrieri, P.; Zaleznik, D.F.; Baker, C.J. Group B streptococcal colonization and serotype-specific immunity in pregnant women at delivery. Obstet. Gynecol. 2000, 96, 498–503.
  131. Le Doare, K.; Heath, P.T. An overview of global GBS epidemiology. Vaccine 2013, 31, D7–D12.
  132. Berner, R. Group B streptococci during pregnancy and infancy. Curr. Opin. Infect. Dis. 2002, 15, 307–313.
  133. Edwards, M.S.; Baker, C.J. Group B streptococcal infections in elderly adults. Clin. Infect. Dis. 2005, 41, 839–847.
  134. Foxman, B. The epidemiology of urinary tract infection. Nat. Rev. Urol. 2010, 7, 653–660.
  135. Tan, C.K.; Ulett, K.B.; Steele, M.; Benjamin, W.H.; Ulett, G.C. Prognostic value of semi-quantitative bacteruria counts in the diagnosis of group B streptococcus urinary tract infection: A 4-year retrospective study in adult patients. BMC Infect. Dis. 2012, 12, 273.
  136. Ulett, K.B.; Benjamin, W.H.; Zhuo, F.; Xiao, M.; Kong, F.; Gilbert, G.L.; Schembri, M.A.; Ulett, G.C. Diversity of group B streptococcus serotypes causing urinary tract infection in adults. J. Clin. Microbiol. 2009, 47, 2055–2060.
  137. Farley, M.M. Group B streptococcal disease in nonpregnant adults. Clin. Infect. Dis. 2001, 33, 556–561.
  138. Anderson, B.L.; Simhan, H.N.; Simons, K.M.; Wiesenfeld, H.C. Untreated asymptomatic group B streptococcal bacteriuria early in pregnancy and chorioamnionitis at delivery. Am. J. Obstet. Gynecol. 2007, 196, 524.e1–524.e5.
  139. Møller, M.; Thomsen, A.C.; Borch, K.; Dinesen, K.; Zdravkovic, M. Rupture of fetal membranes and premature delivery associated with group B streptococci in urine of pregnant women. Lancet 1984, 2, 69–70.
  140. McKenna, D.S.; Matson, S.; Northern, I. Maternal group B streptococcal (GBS) genital tract colonization at term in women who have asymptomatic GBS bacteriuria. Infect. Dis. Obstet. Gynecol. 2003, 11, 203–207.
  141. Kessous, R.; Weintraub, A.Y.; Sergienko, R.; Lazer, T.; Press, F.; Wiznitzer, A.; Sheiner, E. Bacteruria with group-B streptococcus: Is it a risk factor for adverse pregnancy outcomes? J. Matern. Fetal Neonatal Med. 2012, 25, 1983–1986.
  142. Schrag, S.; Gorwitz, R.; Fultz-Butts, K.; Schuchat, A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm. Rep. 2002, 51, 1–22.
  143. Kline, K.A.; Schwartz, D.J.; Lewis, W.G.; Hultgren, S.J.; Lewis, A.L. Immune activation and suppression by group B streptococcus in a murine model of urinary tract infection. Infect. Immun. 2011, 79, 3588–3595.
  144. Ulett, G.C.; Webb, R.I.; Ulett, K.B.; Cui, X.; Benjamin, W.H.; Crowley, M.; Schembri, M.A. Group B Streptococcus (GBS) urinary tract infection involves binding of GBS to bladder uroepithelium and potent but GBS-specific induction of interleukin 1alpha. J. Infect. Dis. 2010, 201, 866–870.
  145. Patras, K.A.; Coady, A.; Babu, P.; Shing, S.R.; Ha, A.D.; Rooholfada, E.; Brandt, S.L.; Geriak, M.; Gallo, R.; Nizet, V. Host Cathelicidin Exacerbates Group B Streptococcus urinary tract infection. mSphere 2020, 5, e00932-19.
  146. Leclercq, S.Y.; Sullivan, M.J.; Ipe, D.S.; Smith, J.P.; Cripps, A.W.; Ulett, G.C. Pathogenesis of Streptococcus urinary tract infection depends on bacterial strain and β-hemolysin/cytolysin that mediates cytotoxicity, cytokine synthesis, inflammation and virulence. Sci. Rep. 2016, 6, 29000.
  147. Jiang, S.M.; Cieslewicz, M.J.; Kasper, D.L.; Wessels, M.R. Regulation of virulence by a two-component system in group B streptococcus. J. Bacteriol. 2005, 187, 1105–1113.
  148. Lamy, M.C.; Zouine, M.; Fert, J.; Vergassola, M.; Couve, E.; Pellegrini, E.; Glaser, P.; Kunst, F.; Msadek, T.; Trieu-Cuot, P.; et al. CovS/CovR of group B streptococcus: A two-component global regulatory system involved in virulence. Mol. Microbiol. 2004, 54, 1250–1268.
  149. Rajagopal, L.; Vo, A.; Silvestroni, A.; Rubens, C.E. Regulation of cytotoxin expression by converging eukaryotic-type and two-component signalling mechanisms in Streptococcus agalactiae. Mol. Microbiol. 2006, 62, 941–957.
  150. Tazi, A.; Disson, O.; Bellais, S.; Bouaboud, A.; Dmytruk, N.; Dramsi, S.; Mistou, M.-Y.; Khun, H.; Mechler, C.; Tardieux, I.; et al. The surface protein HvgA mediates group B streptococcus hypervirulence and meningeal tropism in neonates. J. Exp. Med. 2010, 207, 2313–2322.
  151. Lentini, G.; Midiri, A.; Firon, A.; Galbo, R.; Mancuso, G.; Biondo, C.; Mazzon, E.; Passantino, A.; Romeo, L.; Trieu-Cuot, P.; et al. The plasminogen binding protein PbsP is required for brain invasion by hypervirulent CC17 Group B streptococci. Sci. Rep. 2018, 8, 14322.
  152. Buscetta, M.; Firon, A.; Pietrocola, G.; Biondo, C.; Mancuso, G.; Midiri, A.; Romeo, L.; Galbo, R.; Venza, M.; Venza, I.; et al. PbsP, a cell wall-anchored protein that binds plasminogen to promote hematogenous dissemination of group B Streptococcus. Mol. Microbiol. 2016, 101, 27–41.
  153. De Gaetano, G.V.; Pietrocola, G.; Romeo, L.; Galbo, R.; Lentini, G.; Giardina, M.; Biondo, C.; Midiri, A.; Mancuso, G.; Venza, M.; et al. The Streptococcus agalactiae cell wall-anchored protein PbsP mediates adhesion to and invasion of epithelial cells by exploiting the host vitronectin/α integrin axis. Mol. Microbiol. 2018, 110, 82–94.
  154. Coppolino, F.; Romeo, L.; Pietrocola, G.; Lentini, G.; De Gaetano, G.V.; Teti, G.; Galbo, R.; Beninati, C. Lysine Residues in the MK-Rich Region Are Not Required for Binding of the PbsP Protein From Group B Streptococci to Plasminogen. Front. Cell. Infect. Microbiol. 2021, 11, 679792.
  155. Cook, L.C.C.; Hu, H.; Maienschein-Cline, M.; Federle, M.J. A Vaginal Tract Signal Detected by the Group B Streptococcus SaeRS System Elicits Transcriptomic Changes and Enhances Murine Colonization. Infect. Immun. 2018, 86, e00762-17.
  156. Sullivan, M.J.; Leclercq, S.Y.; Ipe, D.S.; Carey, A.; Smith, J.; Voller, N.; Cripps, A.; Ulett, G. Effect of the Streptococcus agalactiae Virulence Regulator CovR on the Pathogenesis of Urinary Tract Infection. J. Infect. Dis. 2017, 215, 475–483.
  157. Firon, A.; Tazi, A.; Da Cunha, V.; Brinster, S.; Sauvage, E.; Dramsi, S.; Golenbock, D.T.; Glaser, P.; Poyart, C.; Trieu-Cuot, P. The Abi-domain protein Abx1 interacts with the CovS histidine kinase to control virulence gene expression in group B Streptococcus. PLoS Pathog. 2013, 9, e1003179.
  158. Lembo, A.; Gurney, M.A.; Burnside, K.; Banerjee, A.; de los Reyes, M.; Connelly, J.; Lin, W.-J.; Jewell, K.; Vo, A.; Renken, C.; et al. Regulation of CovR expression in Group B Streptococcus impacts blood-brain barrier penetration. Mol. Microbiol. 2010, 77, 431–443.
  159. Patras, K.A.; Wang, N.Y.; Fletcher, E.M.; Cavaco, C.; Jimenez, A.; Garg, M.; Fierer, J.; Sheen, T.; Rajagopal, L.; Doran, K. Group B Streptococcus CovR regulation modulates host immune signalling pathways to promote vaginal colonization. Cell Microbiol. 2013, 15, 1154–1167.
  160. Jacobsen, S.M.; Stickler, D.J.; Mobley, H.L.T.; Shirtliff, M.E. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin. Microbiol. Rev. 2008, 21, 26–59.
  161. Nicolle, L.E. Catheter-related urinary tract infection. Drugs Aging 2005, 22, 627–639.
  162. Old, D.C.; Adegbola, R.A. Haemagglutinins and fimbriae of Morganella, Proteus and Providencia. J. Med. Microbiol. 1982, 15, 551.
  163. Bahrani, F.K.; Mobley, H.L.T. Proteus mirabilis MR/P fimbrial operon: Genetic organization, nucleotide sequence, and conditions for expression. J. Bacteriol. 1994, 176, 3412–3419.
  164. Rocha, S.P.D.; Pelayo, J.S.; Waldir, P. Elias, Fimbriae of uropathogenic Proteus mirabilis. FEMS Immun. Med. Microbiol. 2007, 51, 1–7.
  165. Griffith, D.P.; Musher, D.M.; Itin, C. Urease. The primary cause of infection-induced urinary stones. Investig. Urol. 1976, 13, 346–350.
  166. Chew, R.; Thomas, S.; Mantha, M.L.; Killen, J.P.; Cho, Y.; Baer, R.A. Large urate cystolith associated with Proteus urinary tract infection. Kidney Int. 2012, 81, 802.
  167. Stickler, D.J. Bacterial biofilms in patients with indwelling urinary catheters. Nat. Clin. Pract. Urol. 2008, 5, 598–608.
  168. Jones, B.V.; Mahenthiralingam, E.; Sabbuba, N.A.; Stickler, D.J. Role of swarming in the formation of crystalline Proteus mirabilis biofilms on urinary catheters. J. Med. Microbiol. 2005, 54, 807–813.
  169. Li, X.; Zhao, H.; Lockatell, C.V.; Drachenberg, C.B.; Johnson, D.E.; Mobley, H.L.T. Visualization of Proteus mirabilis within the matrix of urease-induced bladder stones during experimental urinary tract infection. Infect. Immun. 2002, 70, 389–394.
  170. Jones, B.D.; Lockatell, C.V.; Johnson, D.E.; Warren, J.W.; Mobley, H.L.T. Construction of a urease-negative mutant of Proteus mirabilis: Analysis of virulence in a mouse model of ascending urinary tract infection. Infect. Immun. 1990, 58, 1120–1123.
  171. Sabbuba, N.; Hughes, G.; Stickler, D.J. The migration of Proteus mirabilis and other urinary tract pathogens over Foley catheters. BJU Int. 2002, 89, 55–60.
  172. Stickler, D.; Hughes, G. Ability of Proteus mirabilis to swarm over urethral catheters. Eur. J. Clin. Microbiol. Infect. Dis. 1999, 18, 206–208.
  173. Jones, B.V.; Young, R.; Mahenthiralingam, E.; Stickler, D.J. Ultrastructure of Proteus mirabilis swarmer cell rafts and role of swarming in catheter-associated urinary tract infection. Infect. Immun. 2004, 72, 3941–3950.
  174. Jones, S.M.; Yerly, J.; Hu, Y.; Ceri, H.; Martinuzzi, R. Structure of Proteus mirabilis biofilms grown in artificial urine and standard laboratory media. FEMS Microbiol. Lett. 2007, 268, 16–21.
  175. Jiang, S.S.; Liu, M.C.; Teng, L.J.; Wang, W.B.; Hsueh, P.R.; Liaw, S.J. Proteus mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion. Antimicrob. Agents Chemother. 2010, 54, 1564–1571.
  176. Wang, W.B.; Chen, I.C.; Jiang, S.S.; Chen, H.R.; Hsu, C.Y.; Hsueh, P.R.; Hsu, W.B.; Liaw, S.J. Role of RppA in the regulation of polymyxin b susceptibility, swarming, and virulence factor expression in Proteus mirabilis. Infect. Immun. 2008, 76, 2051–2062.
  177. Lin, W.Y.; Lee, Y.J.; Yu, P.H.; Tsai, Y.L.; She, P.Y.; Li, T.S.; Liaw, S.J. The QseEF Two-Component System-GlmY Small RNA Regulatory Pathway Controls Swarming in Uropathogenic Proteus mirabilis. Int. J. Mol. Sci. 2022, 23, 487.
  178. Lecuru, M.; Nicolas-Chanoine, M.H.; Tanaka, S.; Montravers, P.; Armand-Lefevre, L.; Denamur, E.; Mammeri, H. Emergence of Imipenem Resistance in a CpxA-H208P-Variant-Producing Proteus mirabilis Clinical Isolate. Microb. Drug Resist. 2021, 27, 747–751.
  179. Masi, M.; Pinet, E.; Pagès, J.M. Complex Response of the CpxAR Two-Component System to β-Lactams on Antibiotic Resistance and Envelope Homeostasis in Enterobacteriaceae. Antimicrob. Agents Chemother. 2020, 64, e00291-20.
  180. Tierney, A.R.; Rather, P.N. Roles of two-component regulatory systems in antibiotic resistance. Future Microbiol. 2019, 14, 533–552.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback